Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by Fmr LLC

Fmr LLC trimmed its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 11.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,678,527 shares of the company’s stock after selling 2,532,109 shares during the quarter. Fmr LLC owned about 0.09% of Taysha Gene Therapies worth $37,544,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Creative Planning acquired a new stake in shares of Taysha Gene Therapies during the third quarter worth $28,000. China Universal Asset Management Co. Ltd. raised its position in Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after buying an additional 17,446 shares during the last quarter. Privium Fund Management B.V. lifted its stake in shares of Taysha Gene Therapies by 21.8% in the 3rd quarter. Privium Fund Management B.V. now owns 120,000 shares of the company’s stock worth $241,000 after acquiring an additional 21,500 shares during the period. Principal Financial Group Inc. purchased a new stake in shares of Taysha Gene Therapies in the second quarter valued at about $48,000. Finally, Quantum Private Wealth LLC increased its stake in shares of Taysha Gene Therapies by 4.6% during the second quarter. Quantum Private Wealth LLC now owns 730,520 shares of the company’s stock worth $1,636,000 after acquiring an additional 32,000 shares during the period. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. JMP Securities restated a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Canaccord Genuity Group raised their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a report on Friday, November 15th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies currently has an average rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $2.48 on Monday. The company has a market cap of $508.25 million, a P/E ratio of 3.94 and a beta of 0.79. The business has a 50 day moving average of $2.11 and a two-hundred day moving average of $2.38. Taysha Gene Therapies, Inc. has a 52 week low of $1.19 and a 52 week high of $4.32. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.